β-hydroxybutyrate resensitizes colorectal cancer cells to oxaliplatin by suppressing H3K79 methylation in vitro and in vivo

Abstract Background Ketone β-hydroxybutyrate (BHB) has been reported to prevent tumor cell proliferation and improve drug resistance. However, the effectiveness of BHB in oxaliplatin (Oxa)-resistant colorectal cancer (CRC) and the underlying mechanism still require further proof. Methods CRC-Oxa-res...

Full description

Saved in:
Bibliographic Details
Main Authors: Meng Deng (Author), Peijie Yan (Author), Hui Gong (Author), Guiqiu Li (Author), Jianjie Wang (Author)
Format: Book
Published: BMC, 2024-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_2aa3d3dbc061442a89dacfde5c93e6d8
042 |a dc 
100 1 0 |a Meng Deng  |e author 
700 1 0 |a Peijie Yan  |e author 
700 1 0 |a Hui Gong  |e author 
700 1 0 |a Guiqiu Li  |e author 
700 1 0 |a Jianjie Wang  |e author 
245 0 0 |a β-hydroxybutyrate resensitizes colorectal cancer cells to oxaliplatin by suppressing H3K79 methylation in vitro and in vivo 
260 |b BMC,   |c 2024-06-01T00:00:00Z. 
500 |a 10.1186/s10020-024-00864-1 
500 |a 1528-3658 
520 |a Abstract Background Ketone β-hydroxybutyrate (BHB) has been reported to prevent tumor cell proliferation and improve drug resistance. However, the effectiveness of BHB in oxaliplatin (Oxa)-resistant colorectal cancer (CRC) and the underlying mechanism still require further proof. Methods CRC-Oxa-resistant strains were established by increasing concentrations of CRC cells to Oxa. CRC-Oxa cell proliferation, apoptosis, invasion, migration, and epithelial-mesenchymal transition (EMT) were checked following BHB intervention in vitro. The subcutaneous and metastasis models were established to assess the effects of BHB on the growth and metastasis of CRC-Oxa in vivo. Eight Oxa responders and seven nonresponders with CRC were enrolled in the study. Then, the serum BHB level and H3K79me, H3K27ac, H3K14ac, and H3K9me levels in tissues were detected. DOT1L (H3K79me methyltransferase) gene knockdown or GNE-049 (H3K27ac inhibitor) use was applied to analyze further whether BHB reversed CRC-Oxa resistance via H3K79 demethylation and/or H3K27 deacetylation in vivo and in vitro. Results Following BHB intervention based on Oxa, the proliferation, migration, invasion, and EMT of CRC-Oxa cells and the growth and metastasis of transplanted tumors in mice were suppressed. Clinical analysis revealed that the differential change in BHB level was associated with drug resistance and was decreased in drug-resistant patient serum. The H3K79me, H3K27ac, and H3K14ac expressions in CRC were negatively correlated with BHB. Furthermore, results indicated that H3K79me inhibition may lead to BHB target deletion, resulting in its inability to function. Conclusions β-hydroxybutyrate resensitized CRC cells to Oxa by suppressing H3K79 methylation in vitro and in vivo. 
546 |a EN 
690 |a Colorectal cancer 
690 |a Β-hydroxybutyrate 
690 |a Oxaliplatin 
690 |a Drug resistance 
690 |a H3K79me 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Biochemistry 
690 |a QD415-436 
655 7 |a article  |2 local 
786 0 |n Molecular Medicine, Vol 30, Iss 1, Pp 1-15 (2024) 
787 0 |n https://doi.org/10.1186/s10020-024-00864-1 
787 0 |n https://doaj.org/toc/1528-3658 
856 4 1 |u https://doaj.org/article/2aa3d3dbc061442a89dacfde5c93e6d8  |z Connect to this object online.